2023 was a tough yr for that biopharma business, with a number of organizations downsizing and restructuring their workforces to remain afloat. There are actually signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifetime sciences business during the latter A part of 2023 and also https://sites.google.com/view/bio-sites/blog